Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × copper dotatate CU-64 × 1 year × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡